Today's Date: May 19, 2013 Search | Home | Contact | Services | Patent Attorney | Patent Search | Provisional Patent Application | Patent Application | Software Patent | Confidentiality Agreements

USPTO Agrees to Withdraw Claims & Continuations Rules


Written by Gene Quinn
Patent Attorney & Founder of IPWatchdog
Zies, Widerman & Malek
Follow Gene on Twitter @IPWatchdog
Posted: Oct 8, 2009 @ 4:56 pm
View Gene Quinn's profile on LinkedIn
Tell A Friend!


PRESS RELEASE:

GlaxoSmithKline (NYSE: GSK) today announced that it has reached agreement with the United States Patent and Trademark Office (USPTO) to join the USPTO’s motion to dismiss its litigation over Final Regulations published in August 2007 (Triantafyllos Tafas and SmithKline Beecham Corporation, SmithKline Beecham PLC and Glaxo Group Limited vs. David J. Kappos and the United States Patent and Trademark Office). GSK and the USPTO will file a joint motion with the U.S. Court of Appeals for the Federal Circuit to dismiss the litigation and to vacate the previous decision in this case by the U.S. District Court for the Eastern District of Virginia. The USPTO is withdrawing all regulations under dispute.

“We applaud the Patent and Trademark Office for its leadership in deciding to withdraw these rules, which we believe would have harmed innovation across all industries, and specifically would have deprived GSK and other manufacturers of the patent protection necessary to promote medical research and innovation,” said Sherry Knowles, Senior Vice President and Chief Intellectual Patent Counsel, GlaxoSmithKline. “We look forward to working with David Kappos, the recently appointed Director of the USPTO, and others at the Patent and Trademark Office to ensure a patent law framework which promotes the investment that is essential to all innovation, and importantly, to discovering, developing and bringing lifesaving medicines to patients.”

In October 2007, GSK filed and was granted a motion to preliminarily enjoin the PTO from implementing new rules related to patent applications. Those rules were due to become effective in November 2007. In April 2008, the district court ruled on the merits of GSK’s and co-plaintiff Tafas’s challenge and permanently enjoined the USPTO from implementing them on the basis that they were substantive in nature and exceeded the USPTO’s procedural rulemaking authority. In March 2009, on appeal, a divided panel of the Federal Circuit affirmed that judgment in part, and reversed it in part. In July 2009, the Federal Circuit vacated the divided-panel decision and agreed to hear the matter en banc.

The withdrawal of the Final Regulations means that the patent system that had been in place before this litigation will remain in place.



About the Author

Gene Quinn is a US Patent Attorney, law professor and the founder of IPWatchdog.com. He is also a principal lecturer in the top patent bar review course in the nation, which helps aspiring patent attorneys and patent agents prepare themselves to pass the patent bar exam. Gene started the widely popular intellectual property website IPWatchdog.com in 1999, and since that time the site has had many millions of unique visitors. Gene has been quoted in the Wall Street Journal, the New York Times, the LA Times, USA Today, CNN Money, NPR and various other newspapers and magazines worldwide. He represents individuals, small businesses and start-up corporations. As an electrical engineer with a computer engineering focus his specialty is electronic and computer devices, Internet applications, software and business methods.

4 comments
Leave a comment »

  1. So, when did you write the post that asked the PTO to withdraw the rules? Really, they need to keep up! But, at least they did come to their senses post election. Hopefully the folks working on Patent Reform will listen ahead of time as opposed to after-the-fact. The system needs tweaks here and there not wholesale reform.

  2. Gene,

    Good riddance. Tafas, GSK, David Boundy, Richard Belzer, and Ron Katznelson are to be commended for resisting this monstrous abuse of authority by the prior PTO hiearchy. What a collossal waste time and money for all involved. And a complete “thumbs down” on ever granting the PTO substantive rulemaking authority!

  3. Hooray! Now we can re-start SOLVING problems in the system rather than expending energy fighting those who would only desire to create them!

  4. Great news. I just hope my state doesn’t require me to give back the CLE credit I got for going to seminars on the new rules. A huge waste of time and money indeed.

Leave Comment